1. Home
  2. VSTM vs CTKB Comparison

VSTM vs CTKB Comparison

Compare VSTM & CTKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Verastem Inc.

VSTM

Verastem Inc.

HOLD

Current Price

$6.16

Market Cap

723.8M

Sector

Health Care

ML Signal

HOLD

Logo Cytek Biosciences Inc.

CTKB

Cytek Biosciences Inc.

HOLD

Current Price

$5.14

Market Cap

652.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VSTM
CTKB
Founded
2010
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
723.8M
652.1M
IPO Year
2012
2021

Fundamental Metrics

Financial Performance
Metric
VSTM
CTKB
Price
$6.16
$5.14
Analyst Decision
Strong Buy
Hold
Analyst Count
9
5
Target Price
$13.38
$5.70
AVG Volume (30 Days)
2.0M
793.3K
Earning Date
03-19-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$13,379,000.00
$196,828,000.00
Revenue This Year
$208.54
$0.15
Revenue Next Year
$251.40
$5.15
P/E Ratio
N/A
N/A
Revenue Growth
33.79
N/A
52 Week Low
$4.01
$2.37
52 Week High
$11.25
$6.18

Technical Indicators

Market Signals
Indicator
VSTM
CTKB
Relative Strength Index (RSI) 35.18 47.00
Support Level $6.14 $5.14
Resistance Level $6.53 $5.70
Average True Range (ATR) 0.48 0.23
MACD -0.01 -0.05
Stochastic Oscillator 3.12 7.65

Price Performance

Historical Comparison
VSTM
CTKB

About VSTM Verastem Inc.

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

About CTKB Cytek Biosciences Inc.

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

Share on Social Networks: